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oxybutinin treatment and were switched to TER. HRQoL data
were collected through the symptom bother subscale of the
OAB-q questionnaire which was administered at three different
time points: before (M0) and after 3 (M3) and 12 Months or
more (M12) of TER treatment. Efﬁcacy and tolerability of TER
treatment were also investigated. RESULTS: A total of 168
patient questionnaires of M3 and 93 of M12 were compared to
baseline questionnaires (M0). The average age (SD) was 59
(16.9), patients were mainly female (70%). The mean total
score (SD) of the OAB-q subscale decreased from 29.13
(9.12) to 18.16 (7.53) at M3 and to 17.14 (7.01) at M12
(p < 0.001) compared to baseline oxybutinin treatment, exceed-
ing the “Minimally Important Difference” of 10 points. All indi-
vidual OAB-q symptom bother items showed an improvement
with the highest impact on micturition frequency (27% at M3,
30% at M12) and uncomfortable/sudden urge to urinate (28% at
M3, 30% at M12) (p < 0.001). The % of patients reporting
improvement in the treatment related adverse events such as
memory, vertigo, constipation and dry mouth further increased
from M3 to M12 compared to baseline oxybutinin treatment,
with the most pronounced improvement for dry mouth: 58% at
M3, 61% at M12 (p < 0.001). CONCLUSION: The data pre-
sented in this real life study show that TER improved the Health
Related Quality of Life of patients with a neurogenic OAB. Based
upon these results the reimbursement of TER was maintained in
Belgium.
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ILLNESS REPRESENTATIONS IN RENALTRANSPLANT
RECIPIENTS
Valdés C, Moreno D, Ortega T, Ortega F
Hospital Universitario Central de Asturias, Oviedo, Spain
OBJECTIVES: Renal replacement therapy gives rise to range of
beliefs and problems. In order to make sense of and respond to
the illness, patients create their own representations of their
illness. These can including doubts or false beliefs about the
illness, treatment beneﬁts, and compliance. Different representa-
tions have different effects on clinical outcomes, since they are
modulating the relationship between the patient and the illness-
.The aims of this study were, 1) to explore the illness represen-
tations and the relationship with the Health Related Quality of
Life (HRQoL), anxiety and depression; 2) to identify patient
characteristics and factors can inﬂuence them. METHODS: This
is a cross-sectional study with 200 randomized transplant recipi-
ents with different time since transplant. Illness representations
were evaluated using The Revised Illness Perception Question-
naire, the HRQoL using the SF-36 Health Survey and patients
also answered Hospital Anxiety and Depression scale (HADS). A
comorbidity index, sociodemographic and clinical data were also
collected. RESULTS: There are previous results of the ﬁrst 30
patients with at least six months since transplant and the
maximum eighteen months. Higher hospital admissions, higher
comorbidity, and lower hemoglobin and haematocrit levels have
negative inﬂuence on their representations (p < 0.05). On the
other hand illness representations were correlated with the
mental aspects of the HRQoL (p < 0.05), but not with the physi-
cal. To have hereditary renal disease, not to assume the illness as
a chronic, to report higher negative consequences in the diary life
by it, and to perceive lower personal control about the illness,
were correlated with higher anxiety and depression(p < 0.05).
CONCLUSION: Patients’ beliefs are likely to have an important
impact on their adjustment to their illness.To identify those
patients with false or negative beliefs is necessary in order to
avoid lower HRQoL, anxiety, depression, and behaviours such as
noncompliance with immunosuppressants, major cause of renal
transplant failure in younger people.
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CASE1
UTILIZING AN INTERNET-BASED SYSTEMTO DELIVER A
PHARMACY-CENTRIC ALERT AND INTERVENTION IN
A MANAGED CARE SETTING
Fazio J, Orr G, Singal R
WorldDoc, Las Vegas, NV, USA
ORGANIZATION: Medicare Advantage–Prescription Drug
Program Provider. PROBLEM OR ISSUE ADDRESSED: Medi-
care beneﬁciaries with Part-D coverage were consistently reach-
ing their gap in coverage early in the plan year resulting in poor
medication adherence, persistence and treatment outcomes.
GOALS: The organization hoped to improve the cost-
effectiveness of the drug selection choices made by the member
and physician. The organization encouraged its members to
utilize lower cost generic medications to help lower costs and
avoid their coverage gap. OUTCOMES ITEMS USED IN THE
DECISION: Adherence and persistence data and evidence from
other pharmacy-based programs extracted from the literature
was used to determine that the main outcome measure objectives
were to be improved generic utilization, no decrease in essential
maintenance medications, and decreased gross costs per member
per month. IMPLEMENTATION STRATEGY: An internet-
based pharmacy therapy quality assurance system was built to
identify members that were expected to reach their coverage gap
within the plan year. The members’ proﬁles were reviewed by the
staff pharmacist for lower cost therapeutic alternative generic
medications. The members were sent a letter (and possibly their
physician) about available drug alternatives. RESULTS: •16.3%
increased generic utilization vs. 6.8% increase in control group
•2.9% decreased essential medication PMPM vs. 3.8% decrease
in control group •4.5% decrease in gross cost PMPM vs. 5.0%
increase in control group LESSONS LEARNED: That a
pharmacist-driven, internet-based intervention can improve cost-
effective drug therapy. However, the amount of efﬁcient spending
is dependent upon the efﬁciency in which the program is
delivered. Greater efﬁciencies will need to be considered for
broader population exposure.
CASE2
ISSUES WHEN COMPARING COSTS AND EFFECTS OF
INHALED ASTHMA AND COPD MEDICATIONS
Engstrom A1, Hugosson K2
1LFN Pharmaceutical Beneﬁts Board, Solna, Sweden; 2Pharmaceutical
Beneﬁts Board, Solna, Sweden
ORGANIZATION: The Pharmaceutical Beneﬁts Board in
Sweden (LFN) PROBLEM OR ISSUE ADDRESSED: The LFN is
in the process of reviewing the reimbursement status of all phar-
maceuticals. The reviews are done by therapeutic area (based
primarily on ATC3-codes). This is done in order to ensure that all
products used are cost-effective and fulﬁLl the criteria for reim-
bursement. GOALS: To assess the cost-effectiveness of the drugs
used to treat asthma and COPD and to reach a decision on the
continued reimbursement status of these products. The inhaled
medications used for treating asthma and COPD (steroids, beta-
agonists and combinations) are a major part of this therapeutic
area. OUTCOMES ITEMS USED IN THE DECISION: The
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scientiﬁc literature was searched for systematic reviews and
meta-analyses of effectiveness and efﬁcacy data, as well as for
health economic evaluations. IMPLEMENTATION STRAT-
EGY: All currently reimbursed drugs with ATC-codes R03 and
R05 were included in the review. A project team consisting of a
pharmacist, a health economist and a legal advisor led the inves-
tigation. 3 external clinical experts were also attached to the
project group. These experts were recruited based on nomina-
tions from stakeholders, both from the health care system and
patient organizations. Companies marketing a product included
in a review were asked to submit documentation about which
studies best support the effectiveness and cost-effectiveness of
their product. Before the report was published it was sent out for
review by the stakeholders involved. RESULTS: A number of
systematic reviews of a good quality were identiﬁed and were
found to be relevant for the decision situation in Sweden. The
quality of the evidence available to support the different types of
inhaled medicines varied widely. Inhaled steroids, long action
beta-agonists and combinations thereof have a large number of
studies. The short acting beta agonists do not have as much
evidence and the trials available are often small. There is also a
shortage of head to head trials of relevant products at relevant
doses. In this ﬁeld there is also the added complication of differ-
ent inhaler devices in addition to the different active substances.
The value of having a wider range of substances and inhaler
devices has not been studied and quantiﬁed. Based on the avail-
able evidence the products were compared at equivalent doses.
Based on this comparison one product was considered too expen-
sive compared to the alternatives and recommendations were
made on which drugs should primarily be considered for new
patients. The preferred measure of effect in health economic
evaluations the QALY was rarely used within this ﬁeld.
CASE3
REVIEWINGTHE REIMBURSEMENT STATUS OF DRUGS
AGAINST ASTHMA, COPD AND COUGHS
Hugosson H1, Engstrom A2
1Pharmaceutical Beneﬁts Board, Solna, Sweden; 2LFN Pharmaceutical
Beneﬁts Board, Solna, Sweden
ORGANIZATION: The Pharmaceutical Beneﬁts Board in
Sweden (LFN) PROBLEM OR ISSUE ADDRESSED: In Sweden,
the Pharmaceutical Beneﬁts Board (LFN) was instituted in 2002
with the purpose of contributing to a rational and cost-effective
use of pharmaceuticals. The Board’s assignment is to systemati-
cally and in accordance with national prioritization guidelines
decide which pharmaceuticals should be reimbursed. Societal
cost-effectiveness is a key decision parameter. One task of the
LFN is to review the subsidy status of all products (~3 000
products) that were already in the pharmaceutical beneﬁts when
the Board was instituted. All the drugs used for treating asthma,
COPD and coughs (43 products in total)were assessed to see
whether they still merited reimbursement. GOALS: The primary
purpose of the review of these products is to inform the Board’s
decisions on subsidy status for the pharmaceuticals used within
the therapeutic area of asthma, COPD and coughs. The second-
ary purpose is to help other decision makers in Swedish health
care to rationally and cost-effectively use pharmaceuticals in the
treatment of these diseases. OUTCOMES ITEMS USED IN
THE DECISION: The scientiﬁc literature was searched for sys-
tematic reviews and meta-analyses of effectiveness and efﬁcacy
data, evidence on the humanistic burden of disease, as well as for
health economic evaluations. IMPLEMENTATION STRAT-
EGY: All currently reimbursed drugs with ATC-codes R03 and
R05 were included in the review. A project team consisting of a
pharmacist, a health economist and a legal advisor led the inves-
tigation. 3 external clinical experts were also attached to the
project group. These experts were recruited based on nomina-
tions from stakeholders, both from the health care system and
patient organizations. Companies marketing a product included
in a review were asked to submit documentation about which
studies best support the effectiveness and cost-effectiveness of
their product. Before the report was published it was sent out for
review by the stakeholders involved. RESULTS: Of the 43 prod-
ucts reviewed, 34 retained their reimbursement status. Eight
products were removed from reimbursement while limited reim-
bursement was granted for one medicine. Of these nine medi-
cines, ﬁve are cough medicines and four are medicines against
asthma and/or COPD. The four asthma/COPD products were
removed primarily because they were not judged to be cost-
effective. The medicines against cough were removed from
reimbursement due to the severity of the disease being low.
CASE4
DEVELOPMENT ANDVALIDATION OF A CAREGIVER
GASTROENTERORITIS KNOWLEDGE QUESTIONAIRE
Deiratany S
The Hospital for Sick Children,Toronto, ON, Canada
ORGANIZATION: Authors: S, B, Freedman (MD). S, Deiratany
(MD), S, Bensler (MD), R Goldman (MD) (The Department of
Paediatrics, Division of Paediatric Emergency Medicine (S.B.F.,
S.D.) and the Division of Rheumatology (S.B.) The Hospital for
Sick Children, The University of Toronto, Toronto, ON, Canada
and the Division of Pediatric Emergency Medicine (R.D.G.), BC
Children’s Hospital and the Child & Family Research Institute
(CFRI), Department of Pediatrics, University of British Colum-
bia, British Columbia. GOALS: Title: Development and Valida-
tion of a Caregiver Gastroenteritis Knowledge Questionnaire.
OUTCOMES ITEMS USED IN THE DECISION: Background:
Gastroenteritis remains a leading cause of childhood morbidity
and mortality and results in many non-urgent emergency depart-
ment (ED) visits due to caregiver knowledge deﬁciencies. Chil-
dren of caregivers who are less knowledgeable are at increased
risk of presenting to a hospital secondary to dehydration.
IMPLEMENTATION STRATEGY: Purpose: The primary aim
of this study was to describe the reliability and validity of a
Caregiver Gastroenteritis Knowledge Questionnaire (CGKQ).
METHODS: The CGKQ design incorporated 38 true/false ques-
tions covering signs of dehydration, indications to see a physi-
cian, oral re-hydration therapy, solid intake and re-feeding,
medication use and disease transmission. Following validation
procedures, 80 caregivers, 25 nurses and 18 pediatric emergency
medicine physicians and 4 general pediatricians completed the
questionnaire. One month later all participants completed the
questionnaire a second time. RESULTS: Findings: Content valid-
ity was conﬁrmed qualitatively. Construct validity was demon-
strated by incremental increases (P < 0.001) in mean total scores
from caregivers to nurses to physicians at both time points. A
wide range of scores were recorded, from 12 to 38. Multiple
regression analysis revealed the number of prior visits for gastro-
enteritis was inversely associated with overall caregiver score
(P = 0.02). Internal test-retest data gave a single measure intrac-
lass correlation coefﬁcient of 0.74 (95% CI: 0.62, 0.83) and
domain coefﬁcients >0.50 for all domains except for signs of
dehydration. The Pearson correlation coefﬁcient for the test-
retest score was 0.75. Internal consistency was demonstrated
with a Cronbach’s alpha of 0.67 at time 0 and 0.80 at time 1
month. LESSONS LEARNED: The CGKQ is a reliable, valid
tool suitable for identifying knowledge gaps amongst caregivers
and measuring improvement following educational intervention.
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